BioLineRx Ltd. (BLRX)
$1.3
Rating:
Recommendation:
Buy
| Symbol | BLRX |
|---|---|
| Price | $1.3 |
| Beta | 1.482 |
| Volume Avg. | 0.17M |
| Market Cap | 62.206M |
| Shares () | - |
| 52 Week Range | 1.01-3.62 |
| 1y Target Est | - |
| DCF Unlevered | BLRX DCF -> | |
|---|---|---|
| DCF Levered | BLRX LDCF -> | |
| ROE | -49.12% | Strong Sell |
| ROA | -35.45% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 19.54% | Neutral |
| P/E | - | |
| P/B | 0.90 | Buy |
Latest BLRX news
About
Download (Excel)BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.